Business Description
Brooks Laboratories Ltd
ISIN : INE650L01011
Total Employee Number:
323Compare
Compare
Traded in other countries / regions
533543.India IPO Date
2011-09-05Description
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.92 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 0.32 | |||||
Interest Coverage | 6.55 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 5.72 | |||||
Beneish M-Score | -2.02 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.8 | |||||
3-Year Book Growth Rate | 12 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.27 | |||||
9-Day RSI | 28.75 | |||||
14-Day RSI | 34.83 | |||||
3-1 Month Momentum % | 41.57 | |||||
6-1 Month Momentum % | 26 | |||||
12-1 Month Momentum % | -51.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.72 | |||||
Quick Ratio | 1.21 | |||||
Cash Ratio | 0.36 | |||||
Days Inventory | 66.69 | |||||
Days Sales Outstanding | 87 | |||||
Days Payable | 87.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.7 | |||||
Shareholder Yield % | 0.06 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 40.49 | |||||
Operating Margin % | 6.38 | |||||
Net Margin % | 28.67 | |||||
EBITDA Margin % | 31.5 | |||||
FCF Margin % | 6.75 | |||||
OCF Margin % | 10.84 | |||||
ROE % | 21.92 | |||||
ROA % | 17.91 | |||||
ROIC % | 4.51 | |||||
3-Year ROIIC % | 84.74 | |||||
ROC (Joel Greenblatt) % | 80.17 | |||||
ROCE % | 22.07 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 7.37 | |||||
PE Ratio without NRI | 7.37 | |||||
Price-to-Owner-Earnings | 7.21 | |||||
PS Ratio | 2.11 | |||||
PB Ratio | 1.47 | |||||
Price-to-Tangible-Book | 1.46 | |||||
Price-to-Free-Cash-Flow | 31.23 | |||||
Price-to-Operating-Cash-Flow | 19.46 | |||||
EV-to-EBIT | 6.98 | |||||
EV-to-EBITDA | 6.57 | |||||
EV-to-Revenue | 2.08 | |||||
EV-to-FCF | 32.79 | |||||
Price-to-GF-Value | 0.52 | |||||
Price-to-Median-PS-Value | 0.73 | |||||
Price-to-Graham-Number | 0.69 | |||||
| Price-to-Net-Current-Asset-Value | 15.08 | |||||
Earnings Yield (Greenblatt) % | 14.32 | |||||
FCF Yield % | 3.27 | |||||
Forward Rate of Return (Yacktman) % | -16.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Brooks Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 857.384 | ||
| EPS (TTM) (₹) | 8.35 | ||
| Beta | 2.5254 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.29 | ||
| Volatility % | 83.27 | ||
| 14-Day RSI | 34.83 | ||
| 14-Day ATR (₹) | 3.045972 | ||
| 20-Day SMA (₹) | 65.9105 | ||
| 12-1 Month Momentum % | -51.18 | ||
| 52-Week Range (₹) | 36.3 - 164.02 | ||
| Shares Outstanding (Mil) | 29.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Brooks Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Brooks Laboratories Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Brooks Laboratories Ltd Frequently Asked Questions
What is Brooks Laboratories Ltd(NSE:BROOKS)'s stock price today?
The current price of NSE:BROOKS is ₹60.79. The 52 week high of NSE:BROOKS is ₹164.02 and 52 week low is ₹36.30.
When is next earnings date of Brooks Laboratories Ltd(NSE:BROOKS)?
The next earnings date of Brooks Laboratories Ltd(NSE:BROOKS) is .
Does Brooks Laboratories Ltd(NSE:BROOKS) pay dividends? If so, how much?
Brooks Laboratories Ltd(NSE:BROOKS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Brooks Laboratories Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers